Clinical Trial Update: Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects [Phase 2]

View source ↗

Summary

A Phase 2 efficacy and safety trial of Nexagon for persistent corneal epithelial defects was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• NEXAGON

Snippet

Sponsor: University of California, San Francisco | Conditions: Persistent Corneal Epithelial Defects | Phase 2 | Status: TERMINATED | Results posted: 2015-04-20